Targeting the epidermal growth factor receptor for therapy of carcinomas.
As a group, the carcinomas represent a substantial proportion of all human malignancies, but, with relatively few exceptions, current treatments are ineffective. Modification of existing chemotherapeutic agents has not led to significant improvements in the survival of carcinoma patients, and development of new therapeutic strategies is imperative. It is now becoming apparent that activation of the epidermal growth factor receptor (EGF-R) has much wider implications than a straightforward stimulation of cell division. The pleiotropic effects of EGF-R signalling may influence tumour behaviour and the response of carcinomas to treatment; these are important considerations for the development of new therapies that aim to exploit the expression or modulate the function of the EGF-R in these tumours.
Davies
D E
DE
CRC Medical Oncology Unit, Southampton General Hospital, UK.
Chamberlin
S G
SG
D002277:Carcinoma / Q000378:metabolism / Q000628:therapy*; D066246:ErbB Receptors / Q000378:metabolism*; D006801:Humans; D008024:Ligands; D010641:Phenotype
D008024:Ligands; D066246:ErbB Receptors